Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules
暂无分享,去创建一个
[1] T. Watts,et al. TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.
[2] Fumito Ito,et al. Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.
[3] K. Okumura,et al. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival , 2004, Transplant international : official journal of the European Society for Organ Transplantation.
[4] Lieping Chen,et al. Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.
[5] J. Bae,et al. 4‐1BB‐dependent inhibition of immunosuppression by activated CD4+CD25+ T cells , 2004, Journal of leukocyte biology.
[6] S. Quezada,et al. CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.
[7] Youjin Lee,et al. Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.
[8] T. Shiga,et al. Phase II clinical trial of high-dose recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.
[9] T. Taguchi,et al. Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.
[10] G. Zhu,et al. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. , 2004, Blood.
[11] D. Pardoll,et al. Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.
[12] J. Crawford,et al. T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.
[13] Lieping Chen,et al. Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity1 , 2002, The Journal of Immunology.
[14] Aaron J. Johnson,et al. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. , 2002, Cancer research.
[15] J. Alferink,et al. Targeted Disruption of LIGHT Causes Defects in Costimulatory T Cell Activation and Reveals Cooperation with Lymphotoxin β in Mesenteric Lymph Node Genesis , 2002, The Journal of experimental medicine.
[16] M. Fiscella,et al. Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT , 2002, The Journal of Immunology.
[17] Lieping Chen,et al. Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 , 2002, The Journal of Immunology.
[18] A. Dahlin,et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB , 2002, Nature Medicine.
[19] S. Busfield,et al. Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft Survival , 2002, The Journal of experimental medicine.
[20] K. Takeda,et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. , 2002, International immunology.
[21] Aaron J. Johnson,et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. , 2002, The Journal of clinical investigation.
[22] M. Smyth,et al. Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.
[23] David Allman,et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.
[24] M. Smyth,et al. Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.
[25] K. Tamada,et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. , 2001, The Journal of clinical investigation.
[26] C. Ware,et al. Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation, Inflammation, and Tissue Destruction1 2 , 2001, The Journal of Immunology.
[27] B. Hylander,et al. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. , 2001, Cancer research.
[28] D. Olive,et al. The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity1 , 2001, The Journal of Immunology.
[29] K. Schulze-Osthoff,et al. Potential and caveats of TRAIL in cancer therapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[30] Z. Wang,et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.
[31] Y. Sugiyama,et al. CD40‐CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM‐1 and Fas expression and proliferation of human non‐small cell lung tumors , 2001, International journal of cancer.
[32] J. Gribben,et al. A pilot study of combined immunotherapy with autologous adoptive tumour‐specific T‐cell transfer, vaccination with CD40‐activated malignant B cells and interleukin 2 , 2001, British journal of haematology.
[33] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[34] M. Smyth,et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.
[35] B. Dörken,et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity , 2001, Leukemia.
[36] D. Adams,et al. CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily , 2000, Molecular and Cellular Biology.
[37] S. Nagata,et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure , 2000, American Journal of Gastroenterology.
[38] Lieping Chen,et al. LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1 , 2000, The Journal of Immunology.
[39] G. Zhu,et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway , 2000, Nature Medicine.
[40] G. Alvord,et al. Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.
[41] E. Bröcker,et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.
[42] D. Stuart,et al. Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.
[43] A. Eggermont,et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.
[44] M. Ultsch,et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.
[45] L. Cavacini,et al. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] H. Bien,et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.
[47] T. Schumacher,et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.
[48] Peter Scheurich,et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.
[49] Jian Ni,et al. A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis* , 1999, The Journal of Biological Chemistry.
[50] D. Taub,et al. Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand , 1999 .
[51] C. Takahashi,et al. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. , 1999, Journal of immunology.
[52] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[53] D. Adams,et al. CD40 Activation Induces Apoptosis in Cultured Human Hepatocytes via Induction of Cell Surface Fas Ligand Expression and Amplifies Fas-mediated Hepatocyte Death during Allograft Rejection , 1999, The Journal of experimental medicine.
[54] W. Fanslow,et al. Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)* , 1999, The Journal of Biological Chemistry.
[55] Lieping Chen,et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. , 1998, Cellular immunology.
[56] K. Irvine,et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. , 1998, Journal of immunology.
[57] A. Eggermont,et al. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. , 1998, Cancer research.
[58] T. Griffith,et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.
[59] P. Young,et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. , 1998, Journal of immunology.
[60] A. Eggermont,et al. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. , 1998, The Journal of surgical research.
[61] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[62] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[63] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[64] L. Zitvogel,et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. , 1998, Cancer gene therapy.
[65] Lieping Chen,et al. Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway , 1998, European journal of immunology.
[66] C. Ware,et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.
[67] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[68] C. Smith,et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.
[69] C. Ambrose,et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. , 1997, Journal of immunology.
[70] R. Gentz,et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.
[71] W I Wood,et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.
[72] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[73] A. Aruffo,et al. 4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.
[74] Lieping Chen,et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.
[75] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[76] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[77] E. Schattner,et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. , 1996, Blood.
[78] R. Bataille,et al. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. , 1996, Cancer research.
[79] J. Gribben,et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[80] J. Falkenburg,et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. , 1994, Blood.
[81] A. Eggermont,et al. Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .
[82] D. Longo,et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.
[83] J. Banchereau,et al. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells , 1994, The Journal of experimental medicine.
[84] A. Eggermont,et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.
[85] K. Pollok,et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. , 1993, Journal of immunology.
[86] L. Esserman,et al. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. , 1990, Journal of immunology.
[87] A. Jones,et al. Tumour necrosis factor: clinical relevance. , 1989, Cancer surveys.
[88] J. Kovach,et al. A phase I clinical trial of recombinant human tumor necrosis factor , 1988, Cancer.
[89] A. Asher,et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.
[90] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.